Study guide

1.3 Building the Study Plan & Clinical Prioritization Framework

Transplantation and Cellular Therapy Certified Nurse TCTCN

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy

2 Chapter 2: Foundations of Transplantation & Cellular Biology

2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum

3 Chapter 3: Product Collection, Processing & Infusion Procedures

3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking

4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease

4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes

5 Chapter 5: Post-Transplant Infections & Supportive Care

5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition

6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS

6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy

7 Chapter 7: Chronic GVHD & Long-Term Survivorship

7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment

8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards

8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement

1.3 Building the Study Plan & Clinical Prioritization Framework

Key Takeaways Explain This Topic AI

Use the current ONCC content outline to build a realistic calendar that covers all six subject areas, then adjust time to baseline knowledge and practice-question performance; ONCC does not prescribe a preparation-hour minimum.

Apply the nursing process and ordinary clinical-priority principles: address immediate airway, breathing, circulation, neurologic, sepsis, and treatment-toxicity threats before stable surveillance needs.

ONCC does not publish a cognitive-level breakdown for the TCTCN™ test, so treat quoted percentages with suspicion; the outline itself signals a vignette-heavy test because subject areas III and IV are built around management and education rather than definitions.

Anchor every vignette to the therapy type and the day relative to conditioning or infusion, because the differential shifts predictably from conditioning toxicity (Day -7 to 0) to aplasia and CRS (Day +1 to +14), acute GVHD and viral reactivation (Day +15 to +100), and chronic GVHD and late effects beyond Day +100.

Last updated: September 2026

  • Study Strategies & Clinical Decision-Making Framework
  • Designing an Evidence-Based 8-to-12 Week Study Architecture

Preparing for the TCTCN examination requires a structured transition from bedside task execution to advanced clinical decision-making . A focused 8- to 12-week study calendar can distribute practice, retrieval, and remediation without implying that one hour total guarantees readiness.

A four-phase study methodology provides optimal cognitive spacing, active retrieval, and clinical concept consolidation: ┌─────────────────────────────────────────────────────────────────────────────┐

  • │ FOUR-PHASE TCTCN PREPARATION TIMELINE │
  • ├──────────────────────────┬──────────────────────────────────────────────────┤
  • │ Phase 1: Weeks 1–3 │ Foundations & Conditioning Regimens │
  • │ (Knowledge Acquisition) │ Immunology, HLA matching, conditioning/lymphode- │
  • │ │ pletion agents, donor selection, apheresis/DMSO. │
  • ├──────────────────────────┼──────────────────────────────────────────────────┤
  • │ Phase 2: Weeks 4–7 │ Clinical Complications Deep-Dive │
  • │ (Complication Mastery) │ Acute/chronic GVHD staging, SOS/VOD, TA-TMA, │
  • │ │ CRS/ICANS grading (ASTCT consensus), infections. │
  • ├──────────────────────────┼──────────────────────────────────────────────────┤
  • │ Phase 3: Weeks 8–10 │ Clinical Scenarios & Differential Diagnosis │
  • │ (Scenario Drilling) │ Timed question blocks, cue clustering, lab data │
  • │ │ interpretation, emergency intervention triage. │
  • ├──────────────────────────┼──────────────────────────────────────────────────┤
  • │ Phase 4: Weeks 11–12 │ Timed Simulation & Weakness Remediation │
  • │ (Exam Simulation) │ 165-question mock exam, stamina training, review │
  • │ │ of FACT accreditation and regulatory standards. │
  • └──────────────────────────┴──────────────────────────────────────────────────┘
  • Core Study Techniques That Drive Retention

Spaced Retrieval Practice: Test yourself on drug mechanisms (e.g., calcineurin inhibitors vs. mTOR inhibitors vs. antithymocyte globulin) and toxicity grading intervals 3, 7, and 21 days after initial review rather than mass cramming.

Concept Mapping for Overlapping Syndromes: Create side-by-side comparative matrices for syndromes that share clinical features (such as acute liver GVHD vs. SOS/VOD vs. drug-induced cholestasis).

High-Yield Question Deconstruction: When completing practice questions, analyze every incorrect distractor to understand why it is contraindicated, premature, or subordinate in clinical urgency.

Clinical Prioritization Architecture: The TCTCN Nursing Process

ONCC does not publish a cognitive-level breakdown for the TCTCN™ test, so treat any specific percentage quoted elsewhere with suspicion. What the outline does tell you is more useful: subject areas III and IV are built around management and education , not around definitions. Plan for a test dominated by clinical vignettes - complex patients with multisystem laboratory abnormalities and dynamic vital signs - where the work is deciding what to do next rather than recalling a fact.

  • To navigate these questions, use the Clinical Prioritization Hierarchy : ▲
  • / \ LEVEL 1: AIRWAY, BREATHING, CIRCULATION (ABCs)
  • / \ Severe hypoxemia, anaphylaxis, shock, airway edema
  • /─────\
  • / \ LEVEL 2: ACUTE ONCOLOGIC & CELLULAR EMERGENCIES
  • / \ Grade 3-4 CRS, ICANS with airway compromise, severe SOS/VOD,
  • /───────────\ septic shock in neutropenia, hyperacute GVHD
  • / \
  • / \ LEVEL 3: URGENT COMPLICATIONS & PROTOCOL INTERVENTIONS
  • / \ Grade 1-2 CRS, ICE score drop, febrile neutropenia (antibiotics),
  • /───────────────────\ engraftment syndrome, CNI nephrotoxicity, CMV reactivation
  • / \
  • / \ LEVEL 4: SUPPORTIVE CARE & SYMPTOM MANAGEMENT
  • / \ Antiemetics, mucositis pain control, transfusion thresholds,
  • /───────────────────────────\ nutritional support (TPN/enteral)
  • / \
  • / \ LEVEL 5: SURVIVORSHIP, EDUCATION & DISCHARGE
  • / \ Post-HCT vaccination, psychosocial coping, sun protection
  • /───────────────────────────────────\
  • The Five-Step Clinical Decision Algorithm

When reading a clinical vignette:

Identify the Patient Population & Therapy Type: Is the patient undergoing autologous HSCT (no GVHD risk), allogeneic HSCT (GVHD risk, immunosuppressants), or autologous/allogeneic CAR T-cell therapy (CRS/ICANS risk)?

Identify the Timeline (Post-Infusion Day):

Day -7 to Day 0: Conditioning toxicities, DMSO infusion reactions, nausea, hemorrhagic cystitis.

Day +1 to Day +14: Aplasia, neutropenic sepsis, engraftment syndrome, CRS (Days 1–7 post-CAR-T), acute SOS/VOD (peak Days +10 to +20).

Day +15 to Day +100: Acute GVHD (skin, GI, liver), ICANS late presentation, viral reactivations (CMV, HHV-6, BK virus).

Day +100 onward: Chronic GVHD, encapsulated bacterial infections, late organ toxicities, secondary cancers.

Isolate the Emergent Cue Cluster: Look for vital sign instability (hypotension refractory to fluids, SpO2 < 90% on room air), sudden neurological decline (dysgraphia, expressive aphasia, seizure), or abrupt organ dysfunction (doubling of serum creatinine, rapid weight gain, hyperbilirubinemia).

Determine the Immediate Nursing Priority: Is the question asking for the first action (e.g., administer oxygen, stop the infusion, obtain blood cultures) or the definitive medical intervention (e.g., administer tocilizumab, start defibrotide, initiate high-dose methylprednisolone)?

Eliminate Plausible but Secondary Distractors: A distractor may be standard care for a stable patient but fatal if prioritized over an impending airway, circulatory, or neurological collapse.

Weighting Study Time to the Official Blueprint

The most common preparation error is spending time in proportion to interest rather than to the blueprint. The six subject areas are weighted 22 / 22 / 22 / 22 / 8 / 4 percent , and because scoring works from the percentage applied to the scored items, that distribution should shape the calendar directly.

For a 100-hour plan, the arithmetic is straightforward:

Subject area Weight Target hours What that buys

I. Foundations of HSCT and cellular therapy 22% ~22 Immunology, HLA, indications, graft sources, donor and recipient evaluation

II. Process and administration 22% ~22 Collection, conditioning, product administration, acute regimen complications

III. Post-HSCT management and education 22% ~22 GVHD, infection, engraftment, chimerism, late effects

IV. Post-cellular therapy management and education 22% ~22 CRS, ICANS, cytopenias, treatment failure, late effects

  • V. Quality of life 8% ~8 Psychosocial, navigation, sexuality, survivorship, palliative and end-of-life care
  • VI. Professional performance 4% ~4 Scope, evidence-based practice, safety, ethics, accreditation

Two conclusions follow that candidates routinely get wrong in both directions. Areas III and IV together are 44 percent of the exam , so post-therapy management and patient education deserve nearly half the plan, not the tail end of it. And areas V and VI together are only 12 percent , so a candidate who spends three weeks on ethics and accreditation frameworks has misallocated a month - but a candidate who skips them entirely is discarding roughly fifteen scored items, which is a decisive margin on a 125-item scored exam.

Keeping an Error Ledger

Passive review of explanations produces recognition, not recall. Instead, log every missed practice item in a single running document with four columns: the question topic, the answer you chose, the reason the correct answer is better, and the category of error . Categories matter more than content: misread the stem, confused two syndromes, knew the fact but misapplied priority, did not know the fact at all. After fifty items the ledger shows a pattern, and the remediation for "confused two syndromes" is a comparison table while the remediation for "misread the stem" is a reading protocol. Reviewing the ledger, rather than redoing questions, is what converts practice volume into score.